52 results
8-K
EX-99.1
ARVN
Arvinas Inc
7 May 24
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:02am
or metastatic breast cancer.
Received U.S. Food and Drug Administration Fast Track designation for the investigation of vepdegestrant for monotherapy … .
Vepdegestrant has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the investigation of vepdegestrant for monotherapy
8-K
EX-99.1
ARVN
Arvinas Inc
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
for the investigation of vepdegestrant for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth
8-K
EX-10.1
eac5k2ai do1
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
8-K
EX-4.1
009jfca3fi37iob zk
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
EX-1.2
puvj2blj3w2v7sep5t
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.5
ry7a sdt7w4uxr7
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.4
04d vfu6ohux
7 Nov 23
Automatic shelf registration
5:24pm
8-K
EX-99.1
gm4009tb3re3d
8 Aug 23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
aj4 tsokkvggaxxf9q
5 May 23
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:30am
8-K
EX-1.1
334hey1c8 a1k
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.1
21zp0iba9nt3pikxki
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
u1qj7fv 40me2g38abv
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am